Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 2 2Phase 3 1Phase 1 1

Status

Active not recruiting 5Not yet recruiting 1Completed 1

Sponsor Class

INDUSTRY 6NETWORK 1

Study Type

Interventional 7

Sponsor

Cancer Type

Thoracic 7Gastrointestinal 3

Conditions

Carcinoma, Non-Small-Cell Lung 4Lung Neoplasms 3Colorectal Neoplasms 3Small Cell Lung Carcinoma 1Neoplasm Metastasis 1NSCLC 1

Interventions

Carboplatin 347pembrolizumab 322Pemetrexed 246Cisplatin 218Paclitaxel 147Nivolumab 138durvalumab 133osimertinib 112Docetaxel 111atezolizumab 109Specimen Handling 91Radiotherapy 87Drug Therapy 85Magnetic Resonance Spectroscopy 77Etoposide 76Radiosurgery 72Gemcitabine 71Ipilimumab 55130-nm albumin-bound paclitaxel 54Bevacizumab 52cemiplimab 47tislelizumab 44Blood Specimen Collection 40Cetuximab 35Taxes 34Platinum 33Injections 33Biopsy 33Standard of Care 31Immunoglobulin G 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
JDQ443 × Thoracic × 1 year × Clear all
NCT05132075 2026-06-02

KontRASt-02

Novartis

Phase 3 Active not recruiting
95 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05445843 2026-05-14

KontRASt-06

Novartis

Phase 2 Active not recruiting
95 enrolled 20 charts
Thoracic

Lung Neoplasms

NCT05358249 2026-04-14

KontRASt-03

Novartis

Phase 1/2 Active not recruiting
74 enrolled
GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

NCT07468071 2026-04-02

KontRASt-R

Novartis

Phase 1/2 Not yet recruiting
40 enrolled
GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

NCT04699188 2026-03-18

KontRASt-01

Novartis

Phase 1/2 Active not recruiting
344 enrolled
GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis, Colorectal Neoplasms

NCT05714891 2026-02-12

Neoadjuvant Platform Trial in Non-Small Cell Lung Cancer

Canadian Cancer Trials Group

Phase 2 Active not recruiting
4 enrolled
Thoracic

NSCLC

NCT05329623 2025-10-10

A Phase 1 Study to Evaluate the Pharmacokinetics of JDQ443 in Participants With Hepatic Impairment Compared to Matched Healthy Control Participants.

Novartis

Phase 1 Completed
33 enrolled
Thoracic

Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡